‘Aquaman,’ ‘Shazam’ sequels postponed amid Warner Bros. Discovery slate shuffle

‘Aquaman,’ ‘Shazam’ sequels postponed amid Warner Bros. Discovery slate shuffle


Aquaman

Source: Warner Bros. | DC Comics

The release dates for the sequels to “Aquaman” and “Shazam” are being shuffled, as Warner Bros. Discovery seeks to cut costs following its pricey merger.

“Shazam! Fury of the Gods,” which was slated for Dec. 21, has been pushed to March 17, 2023. “Aquaman and the Lost Kingdom,” which was set to debut on that March date is now arriving on Christmas Day in 2023.

The release date shifts comes amid a tumultuous time for the newly formed Warner Bros. Discovery. CEO David Zaslav has been ramping up cost-cutting measures in recent weeks, including layoffs and content eliminations from streaming service HBO Max.

This includes shelving the $90 million “Batgirl” flick that was set to debut on the platform as well as removing nearly 200 “Sesame Street” episodes and dozens of other shows.

It’s likely that the shift of the “Shazam” and “Aquaman” sequels are part of a similar strategy. Marketing theatrical releases is costly, so WarnerBros. Discovery is likely looking to spread out these tentpole releases across two years.

After all, the Dwayne Johnson-led “Black Adam” is set to hit theaters Oct. 21. So instead of having three major DC films released within the span of six months, Warner Bros. Discovery will have five in 14 months. “The Flash” hits theaters June 23, 2023 and “Blue Beetle” arrives August 18, 2023.

Other changes to Warner Bros. Discovery’s release calendar includes dating “House Party” for Dec. 9, 2022, “Evil Dead Rise” for April 21, 2023 and “The Nun 2” for Sept. 8, 2023.

“Salem’s Lot,” which was due out April 21, 2023 is now no longer on the release calendar.



Source

Kimberly-Clark agrees to buy Tylenol owner Kenvue in .7 billion deal, creating consumer staples giant
Business

Kimberly-Clark agrees to buy Tylenol owner Kenvue in $48.7 billion deal, creating consumer staples giant

Huggies, manufactured by Kimberly-Clark and Band-Aid, manufactured by Kenvue. Getty Images Kimberly-Clark announced Monday it’s struck an agreement to buy Kenvue in a deal valued at $48.7 billion that would create a consumer staples giant. The deal is a combination of cash and stock. Shares of Kenvue surged 20% in premarket trading Monday, while shares […]

Read More
Where the blockbuster weight loss drug market stands today — and what’s coming next
Business

Where the blockbuster weight loss drug market stands today — and what’s coming next

A combination image shows an injection pen of Zepbound, Eli Lilly’s weight loss drug, and boxes of Wegovy, made by Novo Nordisk. Hollie Adams | Reuters The appetite for blockbuster weight loss and diabetes drugs is far from satisfied.  From fresh competition to new uses, the market is quickly vaulting into a new stage of […]

Read More
Just 5% of CRE companies have achieved their AI goals. Here’s why
Business

Just 5% of CRE companies have achieved their AI goals. Here’s why

Diminishing perspective of downtown London skyscrapers Chunyip Wong | Istock | Getty Images A version of this article first appeared in the CNBC Property Play newsletter with Diana Olick. Property Play covers new and evolving opportunities for the real estate investor, from individuals to venture capitalists, private equity funds, family offices, institutional investors and large […]

Read More